Physician profile
Katherine Buchowski
NPI 1144246380
$2,416.62
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $921 · 2021: $304 · 2022: $326 · 2023: $40.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $40.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $40.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,157.86 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $226.81 | 2019-2022 | |
| Lundbeck LLC | $173.34 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $160.50 | 2019-2022 | |
| Abbvie INC. | $89.92 | 2021-2023 | Vraylar |
| Vanda Pharmaceuticals INC. | $84.50 | 2019-2022 | |
| Alkermes, INC. | $80.20 | 2019-2021 | |
| Allergan, INC. | $78.45 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.82 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $71.76 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.96 | 2021-2022 | |
| Eisai INC. | $50.57 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $39.51 | 2019-2021 | |
| Indivior INC. | $27.98 | 2022 | |
| Avanir Pharmaceuticals, INC. | $17.05 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $14.26 | 2023 | Quviviq |
| Shire North American Group INC | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Buchowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.